Novel tryptamine derivative and preparation method and application thereof

A derivative, tryptamine technology, applied in the field of medicine, can solve the problems of lack of anti-inflammatory activity research, in-depth research on anti-inflammatory structure-activity relationship, unclear curative effect and application, etc., to improve spatial memory and learning ability, pharmacokinetics, etc. The effect of optimal kinetic parameters

CN111116449APending Publication Date: 2020-05-08LANZHOU UNIVERSITY
4 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2020-05-08

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a novel tryptamine derivative. The novel tryptamine derivative is characterized in that the chemical structural formula of the novel tryptamine derivative is as shown in the specification. According to the invention, an intracerebral tryptamine hormone fragment with an anti-neuroinflammation effect and a non-steroidal anti-inflammatory drug salicylic acid and derivatives thereof are subjected to molecular combination; on one hand, COX effect can be inhibited; and on the other hand, the generation of iNOS and inflammatory factors and the activation of immune cells can beinhibited, and the occurrence and development of inflammations are jointly inhibited through multiple mechanisms. Meanwhile, carboxylic acid groups of salicylic acid non-steroidal anti-inflammatory drugs can be removed, so gastrointestinal side effects caused by acidity are reduced. On such a basis, a series of compounds are designed and synthesized; and enzyme inhibition tests, various immune cell tests and animal in-vivo experimental studies prove that the synthesized compounds have good anti-inflammatory and analgesic activity.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of medicine, and specifically relates to a tryptamine derivative compound and its preparation method, and the application of its salt in the preparation of anti-inflammatory and analgesic drugs, which can be used to prevent and / or treat peripheral inflammation and / or or drugs for central nervous system inflammation. Background technique

[0002] Tryptamine hormones have attracted attention due to their wide range of pharmacological activities. For example, the neurotransmitters 5-hydroxytryptamine (5-HT) and melatonin in the brain have strong antioxidant and free radical scavenging properties, thereby acting as anti-inflammatory, Prevents mitochondrial damage and apoptosis. Among them, melatonin has been proven to inhibit NO production, regulate JNK activation, and Akt / ERK / CREB signaling disorders to improve synaptic dysfunction, memory impairment, neuroinflammation, and neurodegeneration. Asumatriptan and...

Examples

Embodiment 1

[0043] N-(2-(1H-indol-3-yl)ethyl)-2-((3-chloro-2-methylphenyl)amino)benzamide (new tryptamine derivative 1): Add tryptamine ( Formula I, 0.60 mmol) (if formula I is hydrochloride, water and dichloromethane need to be added, the pH of the aqueous phase is adjusted to 11 for extraction, and dried), and 2.5 mL of solvent dichloromethane is added. Add EDCI condensation agent at room temperature, that is, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.60mmol), and simultaneously add catalyst HOBt (1-hydroxybenzotriazole) (0.50mmol) , base triethylamine (1.2mmol), and 2-((3-chloro-2-methylphenyl)amino)benzoic acid (formula II, 0.50mmol) were added and reacted at room temperature for 8h. After the completion of the reaction as monitored by TLC, it was filtered with suction, and the white solid was washed repeatedly with dichloromethane. The organic phase was spin-dried, and the organic phase was dried over anhydrous magnesium sulfate. Purification by silica gel colum...

Embodiment 2

[0045] N-(2-(1H-indol-3-yl)ethyl)-3-hydroxy-2-naphthamide (new tryptamine derivative 2):

[0046] With the method of embodiment 1, tryptamine is formula (I) (formula I), 3-hydroxy-2-naphthamide is (formula II) yield 75%. 1 H NMR(400MHz,DMSO)δ12.13(s,1H),10.87(s,1H), 9.19(t,J=5.4Hz,1H),8.51(s,1H),7.84(d,J=8.2Hz ,1H),7.74(d,J=8.3Hz,1H),7.62(d,J=7.8Hz,1H),7.50(t,J=7.5Hz,1H),7.35(dd,J=11.6,6.0Hz ,2H), 7.28(s,1H),7.23(s,1H),7.08(t,J=7.5Hz,1H),7.00(t,J=7.4Hz,1H),3.66(dd,J=13.3, 7.0Hz, 2H), 3.03(t, J=7.3Hz, 2H). 13 C NMR(101MHz,DMSO)δ168.18, 155.64,136.38,136.11,129.54,128.78,128.30,127.32,126.67,125.88,123.76, 122.88,121.09,118.65,118.40,111.70,111.53,110.83,40.19,25.04.

Embodiment 3

[0048] N-(2-(1H-indol-3-yl)ethyl)-2-hydroxy-4-methylbenzamide (new tryptamine derivative 3): with the method of Example 1, tryptamine is formula (I) (formula I), 2-hydroxy-4-methylbenzamide is (formula II) yield 80%. 1 H NMR (400MHz, DMSO) δ12.73(s, 1H), 10.83(s, 1H), 8.87(t, J=5.4Hz, 1H), 7.73(d, J=8.0Hz, 1H), 7.58(d ,J=7.8Hz,1H),7.35(d,J=8.1Hz,1H),7.18(d,J=1.6Hz,1H),7.07(t,J=7.5Hz,1H),6.99(t,J =7.4Hz,1H), 6.70(d,J=9.2Hz,2H),3.57(dd,J=13.5,7.0Hz,2H),2.97(t,J=7.4Hz,2H),2.27(s,3H ). 13 C NMR (101MHz, DMSO) δ169.20, 160.45, 144.13, 136.34, 127.43, 127.29, 122.77, 121.04, 119.61, 118.36, 118.33, 117.62, 112.53, 111.70, 111.48, 319.90, 2